DAFNA Capital Management cut its holding in Axogen (NASDAQ:AXGN) by 265,456 shares in the fourth quarter, an estimated $6.53 million trade based on quarterly average pricing, according to a February 17, 2026, SEC filing.

According to a SEC filing dated February 17, 2026, DAFNA Capital Management reduced its position in Axogen (NASDAQ:AXGN) by 265,456 shares during the fourth quarter of 2025. The estimated transaction value of the sale is $6.53 million, calculated using the average closing price for the quarter. The fund finished the period with 476,826 shares of Axogen, worth $15.61 million at quarter end.

After the sale, Axogen represents 3.63% of the fund's 13F reportable assets under management.

Top holdings after the filing include:

NASDAQ:RVMD: $48.15 million (11.33% of AUM)

NYSEMKT:XBI: $41.03 million (9.65% of AUM)

NYSEMKT:STXS: $31.47 million (7.40% of AUM)

NASDAQ:ATRC: $23.63 million (5.56% of AUM)

NASDAQ:CYTK: $23.57 million (5.55% of AUM)

As of Friday, AXGN shares were priced at $30.78, up 71% over the past year and well outperforming the S&P 500, which is instead up about 15% in the same period.

Metric

Value

Market Capitalization

$1.6 billion

Revenue (TTM)

$225.2 million

Net Income (TTM)

($15.7 million)

Price (as of Friday)

$30.78

AxoGen develops and markets surgical solutions for peripheral nerve repair, including Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector, AxoGuard Nerve Cap, Avive Soft Tissue Membrane, and AxoTouch two-point discriminator.

The firm generates revenue primarily through the sale of proprietary nerve repair and protection products to healthcare providers and surgical centers.

It serves hospitals, surgery centers, military hospitals, and a range of surgeons in the United States and internationally, including plastic reconstructive, orthopedic, hand, oral, and maxillofacial specialists.

AxoGen, Inc. is a healthcare company specializing in advanced medical devices for peripheral nerve repair and regeneration. The company leverages a portfolio of biologically active grafts and protective devices to address complex nerve injuries, supporting surgeons with clinically differentiated solutions. With a growing international presence and a focus on innovation, AxoGen aims to strengthen its competitive position in the surgical nerve repair market.

This looks less like a loss of conviction and more like discipline after a strong run. When a stock is up more than 70% in a year, trimming can be about portfolio balance rather than a fundamental shift, especially in a fund already concentrated in higher-risk biotech names.

Axogen sits in an interesting middle ground. It is not a pre-revenue biotech swinging on binary trial outcomes. It is a commercial-stage business posting real growth, with revenue up about 20% to $225 million last year and continued double-digit expansion across its core surgical markets. At the same time, profitability remains a work in progress, with a modest net loss and some margin pressure tied to one-time regulatory costs.

The FDA approval of Avance and improved reimbursement dynamics add a clearer path to scale, including higher procedure pricing and broader payer coverage. That is the kind of steady, incremental progress that can compound over time, even if it lacks the explosive upside of earlier-stage biotech bets.

Before you buy stock in Axogen, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axogen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*

Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of March 21, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool recommends SPDR Series Trust - SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.

This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth was originally published by The Motley Fool